Cargando…
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial
BACKGROUND: Currently, there is no US Food and Drug Administration approved therapy for patients with pleural mesothelioma who have relapsed following platinum-doublet based chemotherapy. Vinorelbine has demonstrated useful clinical activity in mesothelioma, however its efficacy has not been formall...
Autores principales: | Fennell, Dean A., Porter, Catharine, Lester, Jason, Danson, Sarah, Taylor, Paul, Sheaff, Michael, Rudd, Robin M, Gaba, Aarti, Busacca, Sara, Nixon, Lisette, Gardner, Georgina, Darlison, Liz, Poile, Charlotte, Richards, Cathy, Jordan, Peter-Wells, Griffiths, Gareth, Casbard, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124711/ https://www.ncbi.nlm.nih.gov/pubmed/35706488 http://dx.doi.org/10.1016/j.eclinm.2022.101432 |
Ejemplares similares
-
BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms
por: Singh, Anita, et al.
Publicado: (2022) -
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
por: Fennell, Dean A, et al.
Publicado: (2021) -
Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial
por: Fennell, Dean A., et al.
Publicado: (2022) -
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
por: Sørensen, J B, et al.
Publicado: (2008) -
BTS guideline for the investigation and management of malignant pleural mesothelioma
por: Woolhouse, Ian, et al.
Publicado: (2018)